Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-27T10:26:31.546Z Has data issue: false hasContentIssue false
  • English
  • Français

Hypertensive Interactions Between Monoamine Oxidase Inhibitors and Foodstuffs

Published online by Cambridge University Press:  29 January 2018

B. Blackwell ,
E. Marley ,
J. Price  and
D. Taylor
B. Blackwell
Affiliation:
The Maudsley Hospital
E. Marley
Affiliation:
Institute of Psychiatry
J. Price
Affiliation:
M.R.C. Psychiatric Genetics Research Unit, Institute of Psychiatry
D. Taylor
Affiliation:
Guys-Maudsley Neurosurgical Unit London, S.E.5
Get access Rights & Permissions [Opens in a new window]

Extract

Hypertensive attacks during treatment with amine oxidase inhibitors were first described in tuberculous patients, and were “rediscovered'’ when these drugs were introduced into psychiatry. In an assessment of iproniazid for tuberculosis (Ogilvie, 1955), 4 out of 42 patients experienced “attacks of a most distressing nature”, with severe throbbing occipital headache and high blood pressure. Six years later, similar attacks were observed in 5 out of 212 patients treated for depression with nialamide (Davies, 1959), but it was not until the introduction of tranylcypromine that reports again appeared (Lurie and Salzer, 1961; Clark, 1961). By the beginning of 1963, over 40 such cases had been reported, including several complicated by intracerebral haemorrhage or cardiac failure due to the rise in blood pressure (Songco, 1961; McClure, 1962; Dorrell, 1963).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 497 , April 1967 , pp. 349 - 365
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aldridge, M., and Oakley, N. (1961). “Tranylcypromine.” Lancet ii, 932.CrossRefGoogle Scholar
Asatoor, A. M., Levi, A. J., and Milne, M. D. (1963). “Tranylcypromine and cheese.” Ibid., ii, 733–734.Google Scholar
Alvarez, W. C. (1924). “Intestinal autointoxication.” Physiol Rev., 4, 352–394.CrossRefGoogle Scholar
Bass, B. H. (1961). “Tranylcypromine.” Lancet, ii, 1099.CrossRefGoogle Scholar
Bethune, H. C., Burrell, R. H., Culpan, R. H., and Ogg, G. J. (1964). “Vascular crises associated with M.A.O.I.” Amer. J. Psychiat., 121, 245–248.CrossRefGoogle Scholar
Blackwell, B. (1963a). “Tranylcypromine.” Lancet, i, 167–168.Google Scholar
Blackwell, B. (1963b). “Tranylcypromine.” Ibid., ii, 414.Google Scholar
Blackwell, B. (1963c). “Hypertensive crisis due to monoamine oxidase inhibitors.” Ibid., ii, 849–851.Google Scholar
Blackwell, B. (1966). “Clinical and pharmacological interactions of monoamine oxidase inhibitors, amines and foodstuffs.” M.D. Thesis, Cambridge University.Google Scholar
Blackwell, B., and Mabbitt, L. A. (1965). “Tyramine in cheese related to hypertensive crises after monoamine oxidase inhibition.” Lancet, i, 938–940.Google Scholar
Blackwell, B., and Marley, E. (1964). “Interaction between cheese and monoamine oxidase inhibitors in rats and cats.” Ibid., i, 530–531.Google Scholar
Blackwell, B., and Marley, E. (1966a). “Interactions of cheese and its constituents with monoamine oxidase inhibitors.” Brit. J. Pharmacol., 26, 120–141.Google Scholar
Blackwell, B., and Marley, E. (1966b). “Interactions of yeast extracts and their constituents with monoamine oxidase inhibitors.” Ibid., 26, 142–161.Google Scholar
Blackwell, B., and Mabbitt, L. A. (1965). “Effects of yeast extract after monoamine oxidase inhibition.” Lancet, i, 940–943.CrossRefGoogle Scholar
Blackwell, B., and Ryle, A. (1964). “Hypertensive crisis associated with monoamine oxidase inhibitors.” Ibid., i, 722–723.Google Scholar
Blackwell, B., and Ryle, A. and Taylor, D. (1965). “Effects of yeast extract after monoamine oxidase inhibition.” Ibid., i, 1166.Google Scholar
Blaschko, H. (1952). “Amine oxidase and amine metabolism.” Pharmacol. Rev., 4, 415–458.Google ScholarPubMed
Blomley, D. J. (1964). “Monoamine oxidase inhibition.” Lancet, ii, 1181–1182.CrossRefGoogle Scholar
Bram, G. (1963). “Side effects of tranylcypromine.” Brit. med. J., ii, 1407.Google Scholar
Brit. Med. J. (1964). Leading article on “Hypertensive reactions to monoamine oxidase inhibitors.” i, 578–579.Google Scholar
Brown, D. D., and Waldron, D. H. (1962). “An unusual reaction to tranylcypromine.” Practitioner, 189, 83–86.Google ScholarPubMed
Burke, C. W., and Lees, F. (1963). “Tranylcypromine.” Lancet, i, 13–16.Google Scholar
Clark, J. A. (1961). “Side effects of tranylcypromine.” Ibid., i, 618–619.Google Scholar
Cooper, A. J., Magnus, R. V., and Rose, M. J. (1964). “A hypertensive syndrome with tranylcypromine medication.” Ibid., i, 527–529.Google Scholar
Dale, H. H., and Dixon, W. E. (1909). “Action of pressor bases produced by putrefaction.” J. Physiol., 34, 25–44.Google Scholar
Dally, P. (1965). In: Scientific Basis of Drug Therapy in Psychiatry. 149–151. Eds. Marks, J. and Pare, C. M. B. London: Pergamon.Google Scholar
Davies, B. E. (1959). “A pilot study of nialamide at Cambridge.” J. Soc. gene. med. Lisboa., 123, 163–172.Google Scholar
Davies, B. E. (1963). “Tranylcypromine and cheese.” Lancet, ii, 691–692.Google Scholar
Davison, A. N. (1958). “Physiological role of monoamine oxidase.” Physiol. Rev., 38, 729–747.Google Scholar
Devadatta, S., Cangadbraram, P. R. J., Andrews, R. H., Fox, W., Ramakrishnan, C V., Selkon, J. B., and Velu, S. (1960). “Peripheral neuritis due to isoniazid.” Bull. World Hlth. Org., 23, 587–598.Google ScholarPubMed
Dixon, W. E. (1913). “A discussion on alimentary toxaemia; its sources, consequences and treatment.” Proc. roy. Soc. Med., 6, pt. 1, 1–380.Google Scholar
Dorrell, W. (1963). “Tranylcypromine and intracranial bleeding.” Lancet, ii, 300.Google Scholar
Epps, H. M. R. (1945). “The development of amine oxidase activity by human tissues after birth.” Biochem. J., 39, 37–42.Google Scholar
Euler, U. S. von, and Hellner-Bjorkman, S. (1955). “Effect of amine oxidase inhibitors on noradrenaline and adrenaline content of cat organs.” Acta physiol. stand., 33, Suppl. 118, 21–25.Google Scholar
Evans, D. A. P., Manley, K. A., and McKusick, V. A. (1960). “Human isoniazid metabolism—a genetically determined phenomenon.” Brit. med. J., ii, 485–491.Google Scholar
Evans, D. A. P., Manley, K. A., Davison, K., and Pratt, R. T. C. (1965). “The influence of acetylator phenotype on the effects of treating depression with phenelzine.” Clin. Pharmac. Ther., 6, 430–435.Google Scholar
Findlay, J. (1911). “The systolic pressure at different points of the circulation in the child and the adult.” Quart. J. Med., 4, 489–497.Google Scholar
Foster, A. R. (1963). “Tranylcypromine and cheese.” Lancet, ii, 587.CrossRefGoogle Scholar
Gates, J. C. (1963). “Reaction to tranylcypromine.” Brit. med. J., ii., 2, 683.Google Scholar
Hare, M. L. C. (1928). “Tyramine oxidase: new enzyme system in liver.” Biochem. J., 22, 968–979.CrossRefGoogle ScholarPubMed
Harper, M. (1964). “Toxic effects of M.A.O.I.” Lancet, ii, 312.Google Scholar
Hodge, J. H., Nye, E. R., and Emerson, G. W. (1964). “Monoamine oxidase inhibitors, broad beans and hypertension.” Ibid., i, 1108.Google Scholar
Horita, A., and McGrath, W. R. (1960). “Specific liver and brain monoamine oxidase inhibition by alkyl and arylalkyl hydrazines.” Proc. Soc. exp. Biol. Med., 103, 753–757.Google Scholar
Horwitz, D., Lovenberg, W., Engelman, K., and Sjoerdsma, A. (1964). “Monoamine oxidase inhibitors, tyramine and cheese.” J. Amer. med. Ass. 188, 1108–1110.Google Scholar
Kalow, W. (1965). “Individual variation in drug metabolism as a cause of drug toxicity. In: Drugs and Enzymes, 4, p. 245–255. eds. Brodie, B. B. and Gillette, J. R. London: Pergarnon.CrossRefGoogle Scholar
Krikler, D. M., and Lewis, B. (1965). “Dangers of natural foodstuffs.” Lancet, i, 1166.CrossRefGoogle Scholar
Levine, R. J., and Sjoerdsma, A. (1963). “Estimation of M.A.O. activity in man: techniques and applications.” Ann. N.Y. Acad. Sci., 107, 966–974.Google Scholar
Liebig, J. (1846). “Baldriansäure und ein neuer Körper aus Käsestoff.” Ann. d. Chem., 57, 127–129.Google Scholar
Lurie, M. L., and Salzer, H. M. (1961). “Tranylcypromine in the ambulatory treatment of depressed patients.” Amer. J. Psychiat., 118, 152–155.Google Scholar
Maher, J. R., Whitney, J. M, Chambers, J. S., and Stamonis, D.J. (1957). “The quantitative determination of isoniazid and paraaminosalicylic acid in body fluids.” Amer. rev. Tuberc, 76, 852–861.Google Scholar
Malmo, R. B., and Shagass, L. (1952). “Studies of B.P. in psychiatric patients under stress.” Psychosom. Med., 14, 82–93.CrossRefGoogle Scholar
Mann, A. M., and Laing, W. A. R. (1963). “Tranylcypromine cephalalgia.” Canad. med. Ass. J., 89, 1115–1118.Google Scholar
Marks, J. (1965). “Interactions involving drugs. In: Scientific Basis of Drug Therapy in Psychiatry. Eds. Marks, J. and Pare, C. M. B., p. 191–201. London: Pergamon.Google Scholar
Martin, G.J. (1942). “The hypertensive effects of diets high in tyrosine.” Arch. Biochem., 1, 397–401.Google Scholar
Mathov, E. (1964). “Risks of monoamine oxidase inhibitors in asthma.” J. Allergy, 34, 483–489.Google Scholar
McClure, J. L. (1962). “Reactions associated with tranylcypromine.” Lancet, i, 1351.CrossRefGoogle Scholar
Medical Letter (1962). ‘Parnate.’ 1, 6–7.Google Scholar
Metchnikoff, E. (1903). The Nature of Man. Ed. and trans. Mitchell, P. G. 72–77; 253–255, London: Heinemann.Google Scholar
Natoff, I. L. (1964). “Cheese and monoamine oxidase inhibitors: interaction in anaesthetized cats.” Lancet, i, 532–533.CrossRefGoogle Scholar
Natoff, I. L. (1965). “Toxic reactions to foodstuffs during therapy with monoamine oxidase inhibitors.” Med. Proc, 11, 101–104.Google Scholar
Nuessle, W. F., Norman, F. C., and Mille, H. E. (1965). “Pickled herring and tranylcypromine reaction.” J. amer. med. Ass., 192, 726–727.Google Scholar
Ogilvie, C. (1955). “The treatment of pulmonary tuberculosis with iproniazid and isoniazid.” Quart. J. Med., 24, 175–189.Google ScholarPubMed
Prescribers Journal (1962). “Antidepressant drugs.” 2, 54.Google Scholar
Proc. Roy. Soc. Med. (1913). “A discussion on alimentary toxaemia; its sources, consequences and treatment.” Proc. roy. Soc. Med., 6, 1–380.Google Scholar
Richmond, P. W., and Roberts, A. H. (1963). “Side effects of tranylcypromine.” Brit. med. J., ii, 999.CrossRefGoogle Scholar
Sadusk, J. F. (1964). “The physician and the food and drug administration.” J.A.M.A., 190, 907–909.CrossRefGoogle ScholarPubMed
Saundy, R. (1913). “A discussion on alimentary toxaemia; its sources, consequences and treatment.” Proc. roy. Soc. Med., 6, pt. 1, 1–380.Google Scholar
Somerville, O. (1913). “A discussion on alimentary toxaemia; its sources, consequences and treatment.” Ibid., 6, pt. 1, 1–380.Google Scholar
Songco, M. F. (1961). “Severe hypertension with parnate.” Amer. J. Psychiat., 118, 360.CrossRefGoogle ScholarPubMed
Van Slyke, L., and Hart, B. (1903). Amer. Chem. J., 30, 8.Google Scholar
Villiers, J. C. (1966). “Intracranial haemorrhage in patients treated with M.A.O. inhibitors.” Brit. J. Psychiat., 112, 109–119.Google Scholar
Wolff, G. H. (1963). “Ch. on headache associated with arterial hypertension.” In: Headache and Head Pain, p. 476–497. New York: Oxford University Press.Google Scholar
Womack, A. M. (1963a). “Sudden death with tranylcypromine.” Brit. med. J., ii, 366.Google Scholar
Womack, A. M. (1963b). “Tranylcypromine.” Lancet, ii, 463.Google Scholar
Zeck, P. (1961). “The dangers of some antidepressant drugs.” Med. J. Aust., 15, ii, 607–608.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.